Asher Bio Announces Clinical Trial Collaboration And Supply Agreement With Amgen On Etakafusp Alfa In Combination With Bispecific T-cell Engager In Patients With Small Cell Lung Cancer
Asher Bio Announces Clinical Trial Collaboration And Supply Agreement With Amgen On Etakafusp Alfa In Combination With Bispecific T-cell Engager In Patients With Small Cell Lung Cancer
Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a clinical trial collaboration and supply agreement with Amgen (NASDAQ:AMGN) to evaluate etakafusp alfa (formerly known as AB248), Asher Bio's investigational CD8+ T cell targeted interleukin-2 (IL-2) immunotherapy, in combination with IMDELLTRA (tarlatamab), Amgen's DLL3-targeting Bispecific T-cell Engager (BiTE) therapy, in patients with extensive-stage small cell lung cancer (ES-SCLC).
Asher Biotherapeutics是一家生物技术公司，专注于开发针对癌症和传染病的精确靶向免疫疗法。今天，该公司宣布与安进（纳斯达克：AMGN）达成临床试验合作和供给协议，以评估其实验性CD8+ T细胞靶向白介素-2（IL-2）免疫疗法etakafusp alfa（以前称为AB248）与安进的DLL3靶向双特异性T细胞连接器（BiTE）疗法IMDELLTRA（tarlatamab）联合应用于广泛期小细胞肺癌（ES-SCLC）患者的效果。